PIK3CA and inflammatory breast carcinoma: We know that PI3K inhibitors have been investigated in many breast cancer trials and have shown promising results in ER-positive endocrine therapy-refractory breast cancer [36], but no clinical trials have been performed specifically in IBC to date.